Zulvac 1 Ovis

RSS

Withdrawn

This medicine's authorisation has been withdrawn

inactivated bluetongue virus, serotype-1
MedicineVeterinaryWithdrawn

Italian is available via eTranslation, the European Commission's machine translation service.

Translate to Italian | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Zulvac 1 Ovis has been withdrawn at the request of the marketing-authorisation holder.

български (BG) (387.71 KB - PDF)

Visualizza

español (ES) (324.29 KB - PDF)

Visualizza

čeština (CS) (367.61 KB - PDF)

Visualizza

dansk (DA) (311.6 KB - PDF)

Visualizza

Deutsch (DE) (339.3 KB - PDF)

Visualizza

ελληνικά (EL) (425.96 KB - PDF)

Visualizza

français (FR) (340.13 KB - PDF)

Visualizza

italiano (IT) (335.8 KB - PDF)

Visualizza

latviešu (LV) (411.71 KB - PDF)

Visualizza

lietuvių (LT) (350.56 KB - PDF)

Visualizza

magyar (HU) (383.87 KB - PDF)

Visualizza

Malti (MT) (373.83 KB - PDF)

Visualizza

Nederlands (NL) (320.6 KB - PDF)

Visualizza

polski (PL) (381.01 KB - PDF)

Visualizza

português (PT) (329.18 KB - PDF)

Visualizza

română (RO) (327.6 KB - PDF)

Visualizza

slovenčina (SK) (357.21 KB - PDF)

Visualizza

slovenščina (SL) (375.83 KB - PDF)

Visualizza

suomi (FI) (335.83 KB - PDF)

Visualizza

svenska (SV) (303.24 KB - PDF)

Visualizza

Product information

български (BG) (747.04 KB - PDF)

Visualizza

español (ES) (415.86 KB - PDF)

Visualizza

čeština (CS) (625.49 KB - PDF)

Visualizza

dansk (DA) (420.56 KB - PDF)

Visualizza

Deutsch (DE) (442.48 KB - PDF)

Visualizza

eesti (ET) (426.62 KB - PDF)

Visualizza

ελληνικά (EL) (744.06 KB - PDF)

Visualizza

français (FR) (441.63 KB - PDF)

Visualizza

hrvatski (HR) (487.06 KB - PDF)

Visualizza

italiano (IT) (439.98 KB - PDF)

Visualizza

latviešu (LV) (612.09 KB - PDF)

Visualizza

lietuvių (LT) (492.04 KB - PDF)

Visualizza

magyar (HU) (645.11 KB - PDF)

Visualizza

Malti (MT) (643.64 KB - PDF)

Visualizza

Nederlands (NL) (428.46 KB - PDF)

Visualizza

polski (PL) (637.5 KB - PDF)

Visualizza

português (PT) (424.02 KB - PDF)

Visualizza

română (RO) (523 KB - PDF)

Visualizza

slovenčina (SK) (629.98 KB - PDF)

Visualizza

slovenščina (SL) (619.27 KB - PDF)

Visualizza

suomi (FI) (412.23 KB - PDF)

Visualizza

svenska (SV) (434.1 KB - PDF)

Visualizza

Íslenska (IS) (431.83 KB - PDF)

Visualizza

norsk (NO) (426.93 KB - PDF)

Visualizza
Latest procedure affecting product information:IB/00017
21/06/2019

български (BG) (853.9 KB - PDF)

Visualizza

español (ES) (837.98 KB - PDF)

Visualizza

čeština (CS) (862.38 KB - PDF)

Visualizza

dansk (DA) (806.02 KB - PDF)

Visualizza

Deutsch (DE) (827.27 KB - PDF)

Visualizza

eesti (ET) (805.45 KB - PDF)

Visualizza

ελληνικά (EL) (877.4 KB - PDF)

Visualizza

français (FR) (824.01 KB - PDF)

Visualizza

italiano (IT) (801.5 KB - PDF)

Visualizza

latviešu (LV) (843.42 KB - PDF)

Visualizza

lietuvių (LT) (1.38 MB - PDF)

Visualizza

magyar (HU) (853.89 KB - PDF)

Visualizza

Malti (MT) (847.1 KB - PDF)

Visualizza

Nederlands (NL) (824.2 KB - PDF)

Visualizza

polski (PL) (862.36 KB - PDF)

Visualizza

português (PT) (837.86 KB - PDF)

Visualizza

română (RO) (1.38 MB - PDF)

Visualizza

slovenčina (SK) (839.69 KB - PDF)

Visualizza

slovenščina (SL) (858.77 KB - PDF)

Visualizza

suomi (FI) (824.89 KB - PDF)

Visualizza

svenska (SV) (805.81 KB - PDF)

Visualizza

Íslenska (IS) (806.86 KB - PDF)

Visualizza

norsk (NO) (804.7 KB - PDF)

Visualizza

Product details

Name of medicine
Zulvac 1 Ovis
Active substance
inactivated bluetongue virus, serotype-1
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotype-1
Species
Sheep
Anatomical therapeutic chemical veterinary (ATCvet) code
QI04AA02

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotypes-1.

Onset of immunity: 21 days after completion of the primary vaccination scheme.

Duration of immunity: 12 months.

Authorisation details

EMA product number
EMEA/V/C/002335

Accelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Marketing authorisation holder
Zoetis Belgium SA

Rue Laid Burniat 1
1348 Louvain-la-Neuve
Belgium

Marketing authorisation issued
05/08/2011
Revision
6

Assessment history

This page was last updated on

Share this page